# Former FDA Director Joins Our Regulatory Path | Eliaz Therapeutics

- Canonical URL: https://wefunder.com/feed/179261
- Entity ID: wefunder:feed_item:179261
- Published at: 2025-02-04 14:06:36 UTC
- Updated at: 2025-07-09 03:41:28 UTC

## Author
Alex Portera

## Subject
Eliaz Therapeutics

## Content
We are thrilled to announce that Dr. Susan Alpert, former Director of the FDA’s Office of Device Evaluation, is joining Eliaz Therapeutics as a regulatory strategist!Dr. Alpert directed all U.S. medical device evaluations at the FDA from 1993 to 1999, during her remarkable 13-year tenure there. She then took her talents to Medtronic, one of the world's largest medical technology companies, where she served as Senior Vice President and Chief Regulatory Officer from 2005 to 2011. Why This Matters for Our MissionGetting innovative medical devices like XGal-3® from lab to patients requires expert navigation of complex FDA requirements. That's where Dr. Alpert's unique background becomes invaluable—she spent six years (1993-1999) directing all medical device evaluations at the FDA, part of her impressive 13-year tenure there. She then brought this regulatory expertise to Medtronic, one of the world's largest medical device companies, where she served as Senior Vice President and Chief Regulatory Officer from 2005 to 2011.About Dr. Alpert:Served as Director of the FDA’s Office of Device Evaluation from 1993 to 1999, where she played a key role in overseeing the review and clearance of medical devices. Throughout her 13-year tenure at the FDA, she held various leadership positions, contributing to regulatory efforts across multiple areas, including drugs, devices, radiological health, and food safety.Global regulatory head for Medtronic, one of the largest med-tech companies (2005-2011).M.D. (University of Miami) and Ph.D. in Biomedical Sciences (NYU).Dr. Alpert's guidance is helping accelerate our mission to bring XGal-3® to the millions fighting sepsis. But it’s your support that truly powers our mission!With deepest gratitude, The Eliaz Therapeutics Team